Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298983 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04298983: Clinical Trial Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT04298983 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04298983, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation therapy (RT) and androgen deprivation therapy (ADT).
Primary Outcome
Clinical response rates will be assessed by percentage of patients who achieve the PSA nadir levels of \< 0.5ng/ml on treatment
Interventions
- RADIATION Radiation Therapy
- DRUG Androgen deprivation therapy (ADT)
- DRUG Abemaciclib 150 MG by mouth twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2024-09-04 |
| Phase | Phase 2 |
Why NCT04298983 stopped before completion
NCT04298983 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT04298983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04298983 about?
NCT04298983 is a clinical study titled "Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer". This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation ...
What is the current status of trial NCT04298983?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2021-02-25. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT04298983?
The interventions under investigation include: Radiation Therapy (RADIATION), Androgen deprivation therapy (ADT) (DRUG), Abemaciclib 150 MG by mouth twice daily (DRUG).
Who is sponsoring clinical trial NCT04298983?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04298983's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI